Lonza to manufacture Alector’s mAb drug candidates for Ph I trial

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/mirror-images)
(Image: Getty/mirror-images)

Related tags: Lonza, Alector, Monoclonal antibodies, Manufacturing, Early phase, Clinical development, Neurology

Lonza will provide manufacturing for Alector’s Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020.

Alector selected Lonza’s Ibex Develop a contract development and manufacturing organization (CDMO) service for the manufacturing of two of its neurodegenerative disease drug candidates in clinical development. The two companies have been collaborating on the early phase development of Alector’s candidates since 2016.

According to a spokesperson for Lonza, the drug candidates are monoclonal antibodies (mAbs) that target the immune system for the treatment of neurodegenerative diseases. The spokesperson added that this approach differs from the current approach of targeting the toxic proteins associated with pathology, such as Tau and beta-amyloid.

Lonza’s GS Xceed gene expression system was used in this collaboration to create high-producing cell lines. Additionally, the two companies have worked together for clinical manufacturing of drug substance and drug product across the Lonza network.

Alector will use the Ibex Develop offering from Lonza which encompasses CDMO services throughout a biopharmaceutical’s life cycle. The Lonza spokesperson told us that Alector will have access to its regulatory team to ensure that its biologics license agreement (BLA) submission is ‘de-risked’ as fast as possible.

Per the agreement, Alector can move molecules for its pipeline in and out of production in accordance with the pace of its clinical trials to ensure the required supply is available.

Lonza will provide its Ibex Develop service out of its Visp, Switzerland site, which is currently undergoing development and is expected to be operational by mid-2020. The company plans to start operations for Alector in Q3 of 2020.

Related news

Show more

Related products

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more